Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Great Leap: Major Chinese Pharmas See Innovative Drug Sales Breakthrough in H1

Others Struggle To Raise Ratio

Executive Summary

A number of major Chinese pharma firms, including Simcere and Hansoh, brought in more revenues from innovative drugs than generics in the first half, a major stand-out from their domestic peers.

You may also be interested in...



3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China

A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.

Cage Fighting: Novel Drugs From MNCs, Chinese Rivals Compete In China Reimbursement Sector

After slashing the prices of their blockbuster drugs to gain wider patient access through China's main reimbursement program, multinationals are now beginning to face increasing challenges from local competitors.

Chinese-Language Podcast: ESMO上的中国数据

Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel